G6PD Deficiency: Tests, Triggers and Everyday Care

Educational guide · Sources checked 8 October 2026

Understanding G6PD deficiency starts with three questions: what the test shows, which exposures need checking, and when symptoms need medical attention. This guide explains the condition and the conversations that support everyday care.

What G6PD deficiency changes in the blood

G6PD deficiency is an inherited difference in the protection of red blood cells. The full name is glucose-6-phosphate dehydrogenase deficiency. Many people feel well for long periods and discover it through testing, a family diagnosis or an episode of illness. Having the condition does not mean that a person is continuously anaemic. It means that particular exposures can make red cells break down more quickly than the body can replace them. ^[1]

This susceptibility is lifelong, even when blood counts are normal and there have been no recent symptoms. Everyday care therefore combines knowledge of the diagnosis with sensible prevention and access to medical advice when something changes. The condition cannot be caught from another person. A person with G6PD deficiency does not need to be separated from classmates, colleagues or family members because of the genetic condition itself. ^[1]

Red cells carry oxygen using haemoglobin. They are continually exposed to chemical reactions involving oxygen, so they need protective systems that limit oxidative damage. G6PD begins a pathway that produces NADPH, a molecule used to maintain those defences. Among its roles, NADPH helps regenerate reduced glutathione. When this protection is inadequate, oxidative stress can damage haemoglobin and the red-cell membrane, making cells more likely to be removed from circulation or rupture. ^[2]

The word “deficiency” can describe an enzyme that is less stable or works less effectively, rather than a complete absence of red blood cells or oxygen. Mature red cells have limited capacity to replace their proteins, which helps explain why the age and condition of the cells matter. This is a problem of cellular protection, not a diagnosis of dietary iron deficiency. Understanding that distinction prevents several common misunderstandings about both test results and treatment. ^[2]

A person can have enough enzyme reserve for ordinary conditions but struggle when an illness or another oxidative exposure increases the demand on that reserve. The amount of working enzyme and the clinical pattern vary. A laboratory value, a named genetic variant and the experience of a previous episode each describe a different part of the picture. None is a complete forecast of the response to every future illness or medicine. ^[3]

Inheritance and why females can also be affected

The G6PD gene is on the X chromosome. With typical XY chromosomes, a person has one gene copy, so a reduced-function variant can directly affect red-cell protection. With typical XX chromosomes, a person has two copies. A father passes his X chromosome to daughters rather than sons. A mother can pass an X-linked variant to a child of either sex. These patterns explain family history without establishing an individual’s result. ^[4]

Females with one altered copy are often called heterozygous or carriers, but “carrier” does not guarantee normal enzyme activity. X-inactivation leaves different cells using different X chromosomes. This mixture can produce near-normal or deficient activity, and some females have haemolysis. Two altered copies can also occur. A genetic result alone cannot measure this mixture. A symptom-free relative does not rule out a variant, and sex alone cannot determine testing or medicine precautions. ^[4]

Different patterns of G6PD deficiency

Most familiar discussions concern episodes triggered by an exposure, with healthier periods between them. Rare forms instead cause ongoing haemolytic anaemia, sometimes called chronic nonspherocytic haemolytic anaemia. In this name, “chronic” refers to continuing red-cell breakdown; “nonspherocytic” distinguishes it from some red-cell membrane disorders. This less common pattern deserves specialist attention because advice designed for an otherwise well person with occasional episodes may not meet the needs of someone with persistent anaemia. ^[6]

Chronic haemolysis can be accompanied by an enlarged spleen, jaundice or gallstones, with considerable variation in severity. An acute illness or oxidising exposure can still worsen the baseline condition. Persistent symptoms should therefore not be dismissed as something everyone with G6PD deficiency must accept. Equally, descriptions of the rare chronic form should not be used to predict complications in every person with a low enzyme result. Clinical history and ongoing measurements establish the relevant pattern. ^[6]

Older websites commonly describe five numbered WHO classes. WHO has since revised the classification of G6PD variants, using categories A, B, C and U. The revision separates variants associated with chronic haemolysis, triggered haemolysis, no established haemolytic phenotype and uncertain clinical significance. The key word is “variants”: the categories organise accumulated evidence about genetic changes. They are not a personal score that replaces a person’s measured enzyme activity or the circumstances of a proposed treatment. ^[5]

A historical class label on a report may still be useful background, but it needs explanation in the context of current terminology. It should not become a promise that an episode will be mild, or that a particular medicine can be taken without checking. Scientific classification changes when evidence improves. Keeping the original laboratory report, including the variant name and testing method when available, allows a specialist to interpret that information without relying on a simplified label copied elsewhere. ^[5]

What blood tests can and cannot tell you

Testing usually begins with the clinical question. Is there evidence that red cells are currently breaking down, is the person anaemic, and could G6PD deficiency explain it? A full blood count measures the effect on the blood, while a reticulocyte count looks at young red cells released by the marrow. A blood film and biochemical markers of haemolysis may add clues. The G6PD assay addresses enzyme activity; it is not interchangeable with these other investigations. ^[7]

An abnormal blood film can suggest oxidative injury, but it does not prove the cause by itself. Likewise, a normal haemoglobin concentration at one visit does not answer whether the person has inherited G6PD deficiency. Clinicians combine the current symptoms with previous jaundice or anaemia, infection history, medicines and relevant family information. This is why a report may include several tests rather than a single result that answers every question about the diagnosis. ^[7]

Qualitative screening and quantitative activity

A qualitative test generally sorts a sample into broad categories such as deficient or apparently normal. It can be useful for detecting marked deficiency, but may miss intermediate activity, particularly in heterozygous females. A quantitative assay provides a numerical activity result. British Society for Haematology guidance emphasises quantitative assessment when screening is abnormal or borderline and warns against relying on a screening test alone for females. The choice of method matters when a treatment decision requires a particular activity assessment. ^[8]

Quantitative testing is more informative, but its number still needs context. It reflects the cells present in the sample, not an individual measurement of every red cell. Laboratory methods, reference intervals and the way activity is expressed affect interpretation. An apparent “normal” flag should not be treated as permission to ignore a conflicting history. A clinician and laboratory can decide whether the method and sample suit the clinical question. ^[8]

Testing during haemolysis or after transfusion

During or shortly after haemolysis, the most vulnerable cells may already have been destroyed. The remaining blood can contain a larger proportion of reticulocytes, which generally have higher G6PD activity than older red cells. As a result, a test can appear normal or higher than expected even when deficiency is present. A result obtained during an episode is useful information, but may not reliably exclude the diagnosis. ^[9]

A recent red-cell transfusion creates another difficulty: donor cells can mask the recipient’s underlying enzyme activity. Tell the ordering clinician about transfusions and recent haemolysis, including approximate dates. Repeat testing may be appropriate when those influences have changed, but the interval should be selected by the clinical team rather than copied from a general article. The need for urgent care or an essential treatment decision must be handled while the diagnostic uncertainty is being resolved. ^[9]

Age also matters when the laboratory interprets an activity measurement. A newborn’s result cannot simply be compared with an adult reference range. A very high white-cell count or other features of the sample can complicate an assay. These limitations do not make testing pointless; they explain why the laboratory report and clinical circumstances belong together. Preserve the units, reference interval and date rather than recording only the word “normal”. ^[3]

Genetic testing answers a related question

A targeted genetic test may examine selected variants rather than every possible change. A negative result therefore needs interpretation according to what was tested. Genetic findings and enzyme activity can complement one another when either result is uncertain. ^[8]

An enzyme test asks how well G6PD is working in the sampled blood. Genetic testing looks for a change in the instructions used to make it. Depending on the situation, a clinician may use one approach or both. A genetic result can help make sense of a family pattern, while an activity result helps describe current red-cell protection. Understanding which question a test addresses makes an apparently complicated investigation easier to follow. ^[10]

When discussing a result, ask whether it establishes the diagnosis, leaves uncertainty, or calls for another assessment. Request an explanation of unfamiliar terms rather than assuming that every flagged item has the same importance. The result should be available to the professionals who prescribe medicines. A useful personal record distinguishes a confirmed diagnosis from a possible family history, and records whom to contact if another clinician needs clarification before making a treatment decision. ^[10]

Recognising haemolysis and seeking timely help

An episode may cause unusual tiredness, pallor, dizziness, a faster heartbeat or shortness of breath. Jaundice and dark, tea-coloured urine can occur as red cells break down. Symptoms differ between people and between episodes. A person does not have to show every sign before seeking assessment. Changes may be more useful than a single impression: for example, becoming much less able to manage usual activity or looking distinctly paler than normal. ^[12]

These symptoms also occur in other illnesses, so they do not diagnose G6PD-related haemolysis at home. A clinician evaluates the severity and possible trigger, and decides whether observation, further tests or hospital care is needed. Some episodes improve as the marrow replaces lost red cells, while severe anaemia may require transfusion. The fact that a previous episode settled without hospital treatment does not reliably establish what care a new episode needs. ^[12]

New jaundice, dark urine or marked fatigue deserve prompt medical advice, especially during an infection or after a new exposure. Rapidly developing, severe symptoms can represent a haemolytic crisis. Emergency care is appropriate when the person is severely breathless, collapsing or profoundly unwell. Do not delay assessment while searching for the precise trigger. Bring medicine names and available results, but gathering paperwork should never take priority over getting urgent help. ^[11]

Haemoglobin released from damaged cells is processed into breakdown products, including bilirubin, which can cause yellowing of the eyes or skin. Some haemoglobin can pass into urine. These visible changes describe consequences of red-cell damage; they do not measure how much oxygen the blood can carry. A person may need blood tests even when the colour change seems modest, particularly if tiredness or breathlessness is increasing. ^[13]

Recovery involves the marrow producing replacement cells, which takes time. The clinical team may follow blood counts and symptoms while addressing the cause of the episode. Follow-up is also an opportunity to clarify what the suspected trigger actually was. An infection and a recently prescribed medicine can occur together, so a careful review is more useful than permanently blaming whichever exposure happened to be noticed first. Future records should reflect the clinician’s assessment and any remaining uncertainty. ^[13]

Newborn jaundice needs its own care plan

G6PD deficiency is an important cause of dangerous newborn jaundice. Care focuses on bilirubin and its potential effects on the developing brain, without waiting for the pattern of anaemia seen in older people. The American Academy of Pediatrics recommends a bilirubin measurement before discharge and follow-up guided by the result for infants born at least 35 weeks’ gestation, the population covered by its guideline. Families need to know when and where the next check happens. ^[14]

A reassuring appearance at discharge is not a substitute for completing that follow-up. Ask the birth team who receives pending results, how the family will be contacted and what to do if jaundice becomes more noticeable before the planned appointment. Tell clinicians about known G6PD deficiency or a relevant family diagnosis. These details help the team connect information across the birth hospital, community services and the baby’s usual clinician. ^[14]

Skin colour alone cannot determine a baby’s bilirubin level, and jaundice may be harder to recognise in darker skin. NICE guidance specifically cautions against estimating bilirubin by visual inspection alone. Jaundice appearing during the first day of life requires urgent medical review. A baby who appears yellow later also needs assessment according to age, symptoms and clinical circumstances, rather than a family deciding that the colour is still within a harmless range. ^[16]

Phototherapy is a medically supervised treatment using appropriate equipment and monitoring. It is not equivalent to placing a baby in sunlight. The team interprets bilirubin against age and risk factors, and selects treatment when indicated. Advice about light treatment should come from the service caring for the baby; a photograph, colour chart or home experiment cannot establish the treatment threshold. Parents should ask for help promptly when a jaundiced baby is feeding poorly or becoming difficult to wake. ^[16]

When bilirubin rises rapidly or does not respond as expected to phototherapy, clinicians reassess the cause and the treatment response. G6PD deficiency is one possible explanation, even without a known family history. Investigations can include blood counts, reticulocytes, a blood film and tests for other causes of haemolysis or illness. Severe cases may need escalation to a neonatal service and, in selected circumstances, exchange transfusion. These decisions require specialist assessment and repeated measurements. ^[17]

Monitoring can continue after phototherapy ends because bilirubin may rise again. Discharge and the timing of another measurement depend on the baby’s circumstances and results. Feeding support is part of care, but adequate feeding alone cannot exclude clinically important jaundice. If enzyme testing is inconclusive during an acute episode, the follow-up plan may also include reassessment of G6PD status. Families should leave knowing which results still need review and which service is responsible for them. ^[17]

Avoid assuming every jaundice episode has the same cause

A known G6PD diagnosis should inform an assessment without ending the search for other explanations. Jaundice can also arise from infection, blood-group incompatibility, liver disease or a problem with bile drainage. Persistent jaundice, pale stools or other unexpected features may call for further investigation. This is particularly important in babies, because delaying the recognition of a different condition can matter even when an inherited red-cell disorder is already documented. ^[18]

Bilirubin itself is a breakdown product, so finding an elevated level is the beginning of an explanation rather than a complete diagnosis. The pattern of results and the child’s examination help clinicians decide what to investigate next. Parents can contribute useful observations about feeding, urine, stools and when the yellowing started. They should describe what they have noticed without needing to decide whether it represents haemolysis, ordinary newborn jaundice or a liver problem. ^[18]

Food, supplements and household exposures

Fava beans, also called broad beans, are an established dietary trigger. They can appear as whole beans or as ingredients in other foods, so the name of a dish alone may not reveal whether it contains them. Checking ingredient labels and asking about unfamiliar preparations is more useful than relying on appearance. A previous occasion without symptoms is not a reliable reason to deliberately try fava beans again after G6PD deficiency has been diagnosed. ^[20]

Keep food conversations specific. Tell the person preparing a meal that the relevant ingredient is fava or broad bean, and use a translated name when needed. General statements such as “cannot eat beans” can confuse the request and unnecessarily narrow food choices. The goal is a clear description of the recognised exposure and a practical way to identify it. Ask the treating team about uncertain ingredients instead of adopting an expanding internet list of prohibited foods. ^[20]

Anaemia does not automatically mean the body needs extra iron. In G6PD-related haemolysis the immediate problem is red-cell breakdown, while iron deficiency is a separate diagnosis that can coexist. The Royal Children’s Hospital advises that iron should be prescribed when iron deficiency is established. A supplement chosen simply because someone looks pale may fail to address the actual cause. The clinician should decide whether iron or another nutrient assessment is appropriate. ^[19]

The same care applies to herbal remedies, concentrated vitamin products and medicines bought without a prescription. Show the actual packaging to a pharmacist or clinician, because ingredients and formulations matter. Describe G6PD deficiency explicitly rather than relying on a label such as “sensitive blood”. Caregivers should know whom to consult before giving an unfamiliar product. This is a manageable communication habit, not a reason to assume every ordinary food or household item is dangerous. ^[19]

Naphthalene-containing mothballs are a recognised concern because naphthalene can damage red cells, with increased susceptibility in G6PD deficiency. Exposure is not limited to swallowing: fumes and contact with stored clothing can matter. Mothballs are pesticides, even when sold for home use. Keep the original packaging, follow storage precautions and avoid exposing a person with G6PD deficiency to naphthalene. Other mothball ingredients can also be toxic, so a different formulation should not be treated as harmless. ^[21]

After a suspected poisoning or significant chemical exposure, contact a poison service or urgent medical service for advice and identify the product if possible. A clinician needs the ingredient and circumstances, not just the description “mothball”. Serious symptoms require emergency care. Do not wait for dark urine to prove that red cells have been affected. Household prevention works best when everyone storing clothes, bedding or pest-control products understands the concern and can check what is being used. ^[21]

Medicine safety depends on the exact product and situation

G6PD medicine advice is specific to the drug, regimen and patient. CPIC evaluates evidence for individual medicines and distinguishes high, medium and low-to-no G6PD-related haemolytic risk. It does not support treating every antibiotic, antimalarial or pain medicine as equally hazardous. Primaquine illustrates why the regimen matters, while nitrofurantoin is placed in the medium-risk category. These categories guide professional decisions, not self-directed changes to treatment. ^[22]

Low-to-no G6PD-specific risk does not mean that a medicine is appropriate for every person or free of other adverse effects. Concurrent illness, other medicines and clinical history also matter. Conversely, a broad warning copied from an older leaflet may not accurately represent the evidence for every member of a drug class. Ask the prescriber or pharmacist to reconcile conflicting advice using current guidance and product information. ^[22]

What regulatory labels add

Product labels can impose specific restrictions. US prescribing information contraindicates Krintafel, a tafenoquine product, in G6PD deficiency or when status is unknown. Elitek, a rasburicase product, and ProvayBlue, a methylene blue injection, also have G6PD-related contraindications. These examples are not a complete avoidance list. Other products still need individual checking. ^{[24] [25] [26]}

ProvayBlue is especially instructive: in G6PD deficiency, methylene blue may be ineffective as well as capable of causing haemolysis. A medicine normally used to address one blood-related emergency can therefore be unsuitable in a different biochemical setting. Emergency teams need to know about G6PD deficiency promptly, even when the presenting problem seems unrelated to previous haemolysis. ^[26]

Pregnancy and breastfeeding checks are also product-specific. Krintafel’s label addresses risks to a fetus or breastfed infant with deficient or unknown G6PD status. A parent’s own result does not answer every question about the baby. The prescriber must assess the exact medicine and both relevant histories. Do not independently stop necessary medication or breastfeeding on the basis of a generic online warning. ^[24]

Rasburicase demonstrates that relevant medicines are used outside malaria care. The European Medicines Agency describes Fasturtec as a treatment for high uric acid associated with particular cancer-treatment situations and states that it must not be used in G6PD deficiency. A haemolysis precaution may therefore become important during an admission for an entirely different condition. Tell hospital teams about the diagnosis rather than assuming the specialty treating the new illness will already have that information. ^[27]

A product’s indication explains why it might be considered; its contraindications identify circumstances in which it should not be used. These are different questions. Comparing a treatment benefit with a G6PD warning requires the actual clinical context and available alternatives. A general article cannot perform that comparison for an individual. An oncology or other specialist team should coordinate with pharmacy and relevant laboratory services when a proposed treatment raises this issue. ^[27]

Travel, infections and vaccination

Before travel, bring G6PD results to the clinician planning malaria prevention or treatment. CDC guidance requires quantitative testing before prescribing relevant primaquine or tafenoquine regimens. The choices also depend on the destination, infection species, pregnancy or breastfeeding and other factors. Do not assume that every malaria medicine is forbidden, or that one previously prescribed product will suit a different journey. Sly Academy’s malaria treatment guide provides broader background for that professional discussion. ^[28]

Fever during or after travel to a malaria-risk area needs prompt assessment, with the travel history and G6PD status disclosed. The condition is not dependable personal protection against malaria. If malaria is diagnosed, treating the acute illness and preventing certain relapses can involve different decisions. A suitable plan must address both the infection and haemolytic risk; postponing medical assessment while trying to choose a medicine online can leave the infection untreated. ^[29]

Infections are among the stresses that can precipitate symptoms, making ordinary preventive care relevant. Children’s Hospital of Philadelphia explains that people with G6PD deficiency are recommended to receive vaccines that help prevent triggering infections. The diagnosis itself is not a general reason to avoid vaccination. A vaccination discussion should still cover the usual individual considerations, including the person’s age, previous reactions and current health, using the recommendations that apply where they receive care. ^[30]

A vaccine and a medicine used for symptoms afterward are separate decisions. If fever or discomfort develops, ask a clinician or pharmacist about an appropriate product rather than extrapolating from a broad online medicine list. Prevention also does not eliminate every infection or every possible trigger. Keep the practical plan for recognising illness and obtaining advice even when routine vaccination is up to date. Good prevention and a clear response plan serve different purposes and work together. ^[30]

Planning everyday life and follow-up

The need for specialist follow-up depends on the clinical pattern, not just the presence of the diagnosis on a record. Perth Children’s Hospital’s referral guidance distinguishes an established, otherwise uncomplicated diagnosis from uncertainty or complications that need further assessment. Local pathways differ, so ask the usual clinician what follow-up is appropriate. Recurrent haemolysis, persistent anaemia or a result that does not fit the history should lead to a more detailed discussion rather than a generic annual-test schedule. ^[31]

An explanation of the diagnosis should include both what to do while well and whom to contact when symptoms develop. This helps prevent follow-up from becoming a series of isolated laboratory numbers. Families can ask what changes would justify earlier review and whether another relative should seek assessment. The purpose is to make the person’s actual needs clear; a specialist referral or the lack of one should not be interpreted as a universal measure of severity. ^[31]

A short personal summary can make appointments easier. Record the confirmed diagnosis, where the original report is stored, the clinician’s contact details and any unresolved question about testing. Keep the current medicine list alongside it. If a reaction has been investigated, distinguish the suspected exposure from the final clinical conclusion. That distinction helps the next professional understand what is known without having to reconstruct a complicated story from memory during an urgent visit.

For school, childcare, work or a trip, agree on a simple communication plan appropriate to the setting. Identify who should receive the care instructions and how they can contact the person or caregiver. An older child or teenager can gradually practise explaining the condition, locating their record and asking for a medicine check. Share the information needed for care while respecting privacy; a diagnosis does not need to become a public description of the person.

Before a planned appointment, write down the decision you need help with. Examples include whether an earlier result was affected by transfusion, how an uncertain ingredient should be checked, or what to bring to a travel consultation. Ask for the answer in a form that can be saved with the report. When a plan changes, replace outdated summaries so that the family, pharmacy and treating team are working from the same information.